Skip to content
Peptidepedia

Liraglutide Dosage Guide: Protocols, Timing & How Much to Take (2026)

From Peptidepedia, the trusted peptide wiki.

Dosage Protocols

Liraglutide dosing differs by indication. Both protocols use gradual titration to minimize gastrointestinal side effects. At any stage, dose escalation can be delayed by one additional week if side effects are not tolerable.

Weight Management (Saxenda Protocol):

  • Week 1: 0.6 mg once daily
  • Week 2: 1.2 mg once daily
  • Week 3: 1.8 mg once daily
  • Week 4: 2.4 mg once daily
  • Week 5 onward: 3.0 mg once daily (maintenance)
The 3.0 mg maintenance dose is the only dose proven effective for weight management. If a patient has not lost at least 4% of body weight after 16 weeks at the full 3.0 mg dose, discontinuation should be considered, as meaningful further weight loss is unlikely.

Type 2 Diabetes (Victoza Protocol):

  • Week 1: 0.6 mg once daily (titration only, not effective for glycemic control)
  • Week 2 onward: 1.2 mg once daily
  • If additional control is needed: 1.8 mg once daily (maximum)
Liraglutide does not require cycling. Clinical evidence supports continuous long-term use for both indications, but weight regain is expected after discontinuation, consistent with the chronic nature of obesity.

Frequently Asked Questions

Both are GLP-1 receptor agonists made by Novo Nordisk. Liraglutide requires daily injections and produces average weight loss of 6 to 8%, while semaglutide is dosed weekly and delivers roughly 15% weight loss. Semaglutide's structural modifications give it a longer half-life (7 days vs 13 hours), making it more convenient and more potent.

Saxenda contains liraglutide 3.0 mg (daily injection) and Wegovy contains semaglutide 2.4 mg (weekly injection). In the head-to-head STEP 8 trial, Wegovy produced 15.8% weight loss compared to 6.4% with Saxenda over 68 weeks. Both are FDA-approved for chronic weight management.

Saxenda follows a 5-week titration schedule. Start at 0.6 mg daily for one week, then increase by 0.6 mg each week until reaching the maintenance dose of 3.0 mg daily. This gradual escalation minimizes gastrointestinal side effects. If a dose increase is not tolerated, delay escalation for an additional week.

The most frequent side effects are gastrointestinal: nausea (39%), diarrhea (21%), constipation (19%), and vomiting (16%). These are most pronounced during dose escalation and typically improve over several weeks. Serious but rare side effects include pancreatitis and gallbladder disease.

In the SCALE Obesity and Prediabetes trial, participants lost an average of 8% of body weight over 56 weeks with liraglutide 3.0 mg plus lifestyle changes, compared to 2.6% with placebo. About 33% of participants achieved 10% or greater weight loss. Early responders who lost 4% or more by week 16 went on to lose an average of 10.8%.

Yes. Victoza is approved for children aged 10 and older with type 2 diabetes (since 2019). Saxenda is approved for adolescents aged 12 and older with obesity (since 2020). A dedicated NEJM trial demonstrated that liraglutide 3.0 mg reduced BMI in adolescents with obesity compared to placebo.

Both contain liraglutide but are approved for different indications and at different doses. Victoza is dosed at 1.2 to 1.8 mg daily for type 2 diabetes, while Saxenda is dosed at 3.0 mg daily for chronic weight management. They should not be used together, and Saxenda should not be used as a diabetes treatment.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). N Engl J Med. 2015;373(1):11-22.
  2. Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016;375(4):311-322.
  3. Davies MJ, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes (SCALE Diabetes). JAMA. 2015;314(7):687-699.
  4. Wadden TA, et al. Liraglutide 3.0 mg and Intensive Behavioral Therapy for Obesity in Primary Care (SCALE IBT). Obesity. 2020;28(3):529-536.
  5. Kelly AS, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020;382(22):2117-2128.
  6. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. 2019;10:155.
  7. Rubino DM, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8). JAMA. 2022;327(2):138-150.
  8. Wadden TA, et al. Weight Maintenance and Additional Weight Loss With Liraglutide After Low-Calorie-Diet-Induced Weight Loss (SCALE Maintenance). Int J Obes. 2013;37(11):1443-1451.
  9. FDA Approval of Saxenda for Weight Management in Patients Aged 12 and Older (2020).
  10. Saxenda (liraglutide) Prescribing Information. Novo Nordisk. 2023.
  11. Victoza (liraglutide) Prescribing Information. Novo Nordisk. 2023.
←Read the full Liraglutide guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”